Nigeria TV Info – Health & Science News

IAVI Reports Successful Phase 1 Trial of Single-Dose Lassa Fever Vaccine

The International AIDS Vaccine Initiative (IAVI), a non-profit scientific research organisation, has announced that its first human trial of a single-dose Lassa fever vaccine has shown promising results, demonstrating safety and durable immunity, paving the way for Phase 2 trials in West Africa.

According to findings published Thursday in the New England Journal of Medicine, the vaccine elicited strong and long-lasting immune responses while maintaining an acceptable safety profile.

The News Agency of Nigeria (NAN) reported that the Phase 1 trial involved 114 healthy volunteers in the United States and Liberia, testing the rVSV∆G-LASV-GPC vaccine at multiple dose levels. Researchers noted that the vaccine was well tolerated, with no serious adverse events reported.

IAVI emphasized that these results mark a significant milestone in the development of a Lassa fever vaccine, a critical tool in combating the often-deadly viral disease that affects thousands annually in West Africa.

The organisation plans to advance the vaccine into Phase 2 trials to further assess its efficacy and safety in larger populations across the region.